Jing Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jing Wu has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Chaoji Shi
17 shared publicationsChenping Zhang
17 shared publicationsGuizhu Yang
17 shared publicationsGuoyu Zhou
17 shared publicationsJiang Li
17 shared publicationsLizhen Wang
17 shared publications
Latest Publications
- Top Cited Papers
- 29 April 2026
- Published by Springer Nature in Nature
- Vol. 653 (8115) , 723-730
Engineering tough blood clots for rapid haemostasis and enhanced regeneration
Blood clots are pivotal for haemostasis and regeneration1, but they are mechanically weak and form slowly2, posing risks for life-threatening haemorrhage and limiting broader applications3,4,5. These limitations are attributed to complex coagulation cascades, abundant mechanically ineffective cells and little structural polymers. Strategies that strengthen polymer networks are inapplicable to these highly cellularized materials. Here we report a strategy that rapidly crosslinks red blood cells into tough cytogels and integrates them within blood clots. The resulting engineered blood clots (EBCs) form within seconds and exhibit a 13-fold increase in fracture toughness, and a 4-fold improvement in adhesion energy compared with native clots. Experiments and modelling identify the rupture of mechanically integrated cells as a key toughening mechanism. In vivo studies demonstrate that EBCs can rapidly halt haemorrhage, promote tissue regeneration, mitigate inflammation and foreign body reactions, and prevent postoperative adhesion. The safety and efficacy of both autologous and allogeneic EBCs were also validated. Our strategy is applicable to a range of cells and polymers. This work may motivate the development and translation of highly cellularized materials for bleeding control, wound management, tissue repair and regenerative medicine.
- 29 April 2026
- Published by Springer Nature in Nature
- Vol. 653 (8115) , 723-730
Top Cited PapersEngineering tough blood clots for rapid haemostasis and enhanced regeneration
Blood clots are pivotal for haemostasis and regeneration1, but they are mechanically weak and form slowly2, posing risks for life-threatening haemorrhage and limiting broader applications3,4,5. These limitations are attributed to complex coagulation cascades, abundant mechanically ineffective cells and little structural polymers. Strategies that strengthen polymer networks are inapplicable to these highly cellularized materials. Here we report a strategy that rapidly crosslinks red blood cells into tough cytogels and integrates them within blood clots. The resulting engineered blood clots (EBCs) form within seconds and exhibit a 13-fold increase in fracture toughness, and a 4-fold improvement in adhesion energy compared with native clots. Experiments and modelling identify the rupture of mechanically integrated cells as a key toughening mechanism. In vivo studies demonstrate that EBCs can rapidly halt haemorrhage, promote tissue regeneration, mitigate inflammation and foreign body reactions, and prevent postoperative adhesion. The safety and efficacy of both autologous and allogeneic EBCs were also validated. Our strategy is applicable to a range of cells and polymers. This work may motivate the development and translation of highly cellularized materials for bleeding control, wound management, tissue repair and regenerative medicine.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Pathway analysis in MM and comparison between MM and CM.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Pathway analysis in MM and comparison between MM and CM.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Significantly mutated genes,promoters and UTRs of MMs.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Significantly mutated genes,promoters and UTRs of MMs.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Whole Genome Sequencing metrics and clinical data of MMs.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Whole Genome Sequencing metrics and clinical data of MMs.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S6 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
GISTIC peaks identified in MMs.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
GISTIC peaks identified in MMs.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S4 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Distribution of chromothripsis and BFB and correlation analysis of the SV pattern and CNV pattern.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Distribution of chromothripsis and BFB and correlation analysis of the SV pattern and CNV pattern.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Supplementary figures and figure legends. (Figure S1) Deregulation of genes within key affected signaling pathways in MM. (Figure S2) Validation of the somatic SNV/InDels found in POM121. (Figure S3) Copy number changes in MM. (Figure S4) Distribution of SVs and genetic events including breakage-fusion-bridges [BFBs] and chromothripsis across chromosomes among all samples. (Figure S5) Validation of SV occurring between chromosome 5 and 12 in MM023 and MM065. (Figure S6) Fine structure of BFBs and chromothripsis found in MM. (Figure S7) Comparison of lesions found in mucosal melanoma. (Figure S8) Validation of the copy number alteration of CDK4 and TERT in representative samples. (Figure S9) FISH confirming amplification and co-localization of CDK4 [12q14] and TERT [5p15]. (Figure S10) Molecular characterization of the MM PDX models and the effects of palbociclib on Rb phosphorylation in treatment-responsive PDX models. (Figure S11) Significant mutated non-coding region genes in MMs. (Figure S12) Mutation signatures found in MM.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Supplementary figures and figure legends. (Figure S1) Deregulation of genes within key affected signaling pathways in MM. (Figure S2) Validation of the somatic SNV/InDels found in POM121. (Figure S3) Copy number changes in MM. (Figure S4) Distribution of SVs and genetic events including breakage-fusion-bridges [BFBs] and chromothripsis across chromosomes among all samples. (Figure S5) Validation of SV occurring between chromosome 5 and 12 in MM023 and MM065. (Figure S6) Fine structure of BFBs and chromothripsis found in MM. (Figure S7) Comparison of lesions found in mucosal melanoma. (Figure S8) Validation of the copy number alteration of CDK4 and TERT in representative samples. (Figure S9) FISH confirming amplification and co-localization of CDK4 [12q14] and TERT [5p15]. (Figure S10) Molecular characterization of the MM PDX models and the effects of palbociclib on Rb phosphorylation in treatment-responsive PDX models. (Figure S11) Significant mutated non-coding region genes in MMs. (Figure S12) Mutation signatures found in MM.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S5 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Comparison between two primary samples and matched metastatic samples.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Comparison between two primary samples and matched metastatic samples.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S4 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Distribution of chromothripsis and BFB and correlation analysis of the SV pattern and CNV pattern.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Distribution of chromothripsis and BFB and correlation analysis of the SV pattern and CNV pattern.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Pathway analysis in MM and comparison between MM and CM.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Pathway analysis in MM and comparison between MM and CM.